Mitochondrial targeted peptides for cancer therapy

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5715-5725

  Farsinejad, Sadaf ^a   Gheisary, Zohre ^a   Ebrahimi Samani, Sanaz ^a   Alizadeh, Ali Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Mitochondria; Peptide; Review

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIMICROBIAL PEPTIDE R7 KLA; ANTINEOPLASTIC AGENT; CALCIUM ION; CELL PENETRATING PEPTIDE; CYTOTOXIC AGENT; DOXORUBICIN; GO 203; HYBRID PROTEIN; KILLERFLIP PEPTIDE; LL 37 HCAP 18 FUSION PROTEIN; MITOCHONDRIAL TARGETED PEPTIDE; MITOCHONDRIAL TARGETING DOMAIN PEPTIDE; NAVITOCLAX; OBATOCLAX; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TAT FHIT FUSION PROTEIN; TAT FUSED IP3R DERIVED PEPTIDE; THREONYLLEUCYLSERYLGLYCYLALANYLPHENYLALANYLGLUTAMYLLEUCYLSERYLARGINYLASPARTYLLYSINE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; CALCIUM; CYTOCHROME C; MITOCHONDRIAL DNA; PEPTIDE; PROTEIN BAX;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CALCIUM SIGNALING; CANCER PATIENT; CANCER THERAPY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HOST RESISTANCE; HUMAN; LEUKEMIA; LYMPHOMA; MITOCHONDRIAL RESPIRATION; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; SOLID TUMOR; APOPTOSIS; GENETICS; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CALCIUM; CYTOCHROMES C; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEPTIDES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84940439721     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3719-1     Document Type: Review

References (90)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol. 2014;35(9):8483–523.
3. Imanieh MH, Bagheri F, Alizadeh AM, Ashkani-Esfahani S. Oxytocin has therapeutic effects on cancer, a hypothesis. Eur J Pharmacol. 2014;741:112–23.
4. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16:3–10.
5. Wu H-C, Chang D-K, Huang C-T. Targeted therapy for cancer. J Cancer Mol. 2006;2:57–66.
6. Neuzil J, Dyason JC, Freeman R, Dong L-F, Prochazka L, Wang X-F, et al. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr. 2007;39:65–72.
7. J. Thundimadathil. Cancer treatment using peptides: current therapies and future prospects. J amino acids. 2012;2012.
8. Sun L. Peptide-based drug development. Mod Chem Appl. 2013;1:e103.
9. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Pept Sci. 2002;66:184–99.
10. Li ZJ, Cho CH. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med. 2012;10:S1.
11. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol. 2006;147:239–48.
12. Whelan RS, Konstantinidis K, Wei A-C, Chen Y, Reyna DE, Jha S, et al. Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci. 2012;109:6566–71.
13. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev. 2002;54:101–27.
14. Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33:341–52.
15. Frezza C, Gottlieb E. Mitochondria in cancer: not just innocent bystanders. in Seminars in Cancer Biol. 2009;4-11.
16. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485–95.
17. Martel C, Huynh LH, Garnier A, Ventura-Clapier R, Brenner C. Inhibition of the mitochondrial permeability transition for cytoprotection: direct versus indirect mechanisms. Biochem Res Int. 2012;2012:213403.
18. Constance JE, Lim CS. Targeting malignant mitochondria with therapeutic peptides. Ther Deliv. 2012;3:961–79.
19. Martinou J-C, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21:92–101.
20. Jacotot E, Costantini P, Laboureau E, Zamzami N, Susin SA, Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Ann N Y Acad Sci. 1999;887:18–30.
21. Alizadeh AM, Faghihi M, Khori V, Sohanaki H, Pourkhalili K, Mohammadghasemi F, et al. Oxytocin protects cardiomyocytes from apoptosis induced by ischemia–reperfusion in rat heart: role of mitochondrial ATP-dependent potassium channel and permeability transition pore. Peptides. 2012;36:71–7.
22. Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–37.
23. Hosseini J, Mahmoodi M, Jalili A, Fakhari S, Hosseini-zijoud S-M, Tahamtan M, et al. Aloe-emodin Induces apoptosis through the up-regulation of Fas in the human breast cancer cell line MCF-7. Life Sci J. 2014;11(2s):47–53.
24. Jabbour AM, Heraud J, Daunt C, Kaufmann T, Sandow J, O'Reilly L, et al. Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ. 2008;16:555–63.
25. Ren D, Tu H-C, Kim H, Wang GX, Bean GR, Takeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX-and BAK-dependent cell death program. Science. 2010;330:1390–3.
26. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–75.
27. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008;27:S149–57.
28. Rooswinkel R, Van De Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis. 2012;3:e366.
29. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–32.
30. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008;100:580–95.
31. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2006;26:2374–80.
32. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–81.
33. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008;27:6646–56.
34. Trudel S, Stewart AK, Li Z, Shu Y, Liang S-B, Trieu Y, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007;13:621–9.
35. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869–80.
36. Rudin CM, Hann CL, Garon EB, De Oliveira MR, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163–9.
37. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–59.
38. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2008;16:360–7.
39. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.
40. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14:3268–77.
41. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.
42. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120–9.
43. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010;66:1079–85.
44. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Madiraju SM, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci. 2007;104:19512–7.
45. Ma C, Yin G, You F, Wei Y, Huang Z, Chen X, et al. A specific cell-penetrating peptide induces apoptosis in SKOV3 cells by down-regulation of Bcl-2. Biotechnol Lett. 2013;35:1791–7.
46. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther. 2003;2:S105–14.
47. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004;101:9381–6.
48. Kardeh S, Ashkani-Esfahani S, Alizadeh AM. Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur J Pharmacol. 2014;735:150–68.
49. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot. 2003;91:179–94.
50. Galindo MF, Jordan J, Gonzalez-Garcia C, Cena V. Reactive oxygen species induce swelling and cytochrome c release but not transmembrane depolarization in isolated rat brain mitochondria. Br J Pharmacol. 2003;139:797–804.
51. Faghihi M, Alizadeh AM, Khori V, Latifpour M, Khodayari S. The role of nitric oxide, reactive oxygen species, and protein kinase C in oxytocin-induced cardioprotection in ischemic rat heart. Peptides. 2012;37:314–9.
52. Petrosillo G, Ruggiero FM, Paradies G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J. 2003;17:2202–8.
53. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147–57.
54. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–89.
55. Nicholls P. Cytochrome c binding to enzymes and membranes. Biochim Biophys Acta. 1974;346:261–310.
56. Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682–90.
57. Yin L, Kufe D. MUC1-C oncoprotein blocks terminal differentiation of chronic myelogenous leukemia cells by a ROS-mediated mechanism. Genes Cancer. 2011;2:56–64.
58. Wierzbicki PM, Adrych K, Kartanowicz D, Dobrowolski S, Stanislawowski M, Chybicki J, et al. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J Physiol Pharmacol. 2009;4:63–70.
59. Yu GR, Qin WW, Li JP, Hua W, Meng YL, Chen R, et al. HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells. Biosci Rep. 2012;32:271–9.
60. Zhivotovsky B, Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium. 2011;50:211–21.
61. Orrenius S, Nicotera P, Zhivotovsky B. Cell death mechanisms and their implications in toxicology. Toxicol Sci. 2011;119:3–19.
62. Norberg E, Gogvadze V, Ott M, Horn M, Uhlen P, Orrenius S, et al. An increase in intracellular Ca2+ is required for the activation of mitochondrial calpain to release AIF during cell death. Cell Death Differ. 2008;15:1857–64.
63. Carafoli E. Calcium signaling: a tale for all seasons. Proc Natl Acad Sci. 2002;99:1115–22.
64. 2+. J Biol Chem. 1984;259:6612–5.
65. Hajnoczky G, Robb-Gaspers LD, Seitz MB, Thomas AP. Decoding of cytosolic calcium oscillations in the mitochondria. Cell. 1995;82:415–24.
66. Seo YW, Woo HN, Piya S, Moon AR, Oh JW, Yun CW, et al. The cell death-inducing activity of the peptide containing Noxa mitochondrial-targeting domain is associated with calcium release. Cancer Res. 2009;69:8356–65.
67. Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, et al. Induction of Ca(2)+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood. 2011;117:2924–34.
68. Brenner C, Cadiou H, Vieira HL, Zamzami N, Marzo I, Xie Z, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene. 2000;19:329–36.
69. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem. 2000;275:12321–5.
70. Rostovtseva TK, Antonsson B, Suzuki M, Youle RJ, Colombini M, Bezrukov SM. Bid, but not Bax, regulates VDAC channels. J Biol Chem. 2004;279:13575–83.
71. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol. 2007;292:C45–51.
72. Pennarun B, Gaidos G, Bucur O, Tinari A, Rupasinghe C, Jin T, et al. killerFLIP: a novel lytic peptide specifically inducing cancer cell death. Cell Death Dis. 2013;4:e894.
73. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology. 2011;216:322–33.
74. Wu WKK, Sung JJY, To KF, Yu L, Li HT, Li ZJ, et al. The host defense peptide LL‐37 activates the tumor‐suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol. 2010;223:178–86.
75. Ren SX, Cheng AS, To KF, Tong JH, Li MS, Shen J, et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 2012;72:6512–23.
76. Chuang C-M, Monie A, Wu A, Mao C-P, Hung C-F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther. 2009;20:303–13.
77. Al-Benna S, Shai Y, Jacobsen F, Steinstraesser L. Oncolytic activities of host defense peptides. Int J Mol Sci. 2011;12:8027–51.
78. Law B, Quinti L, Choi Y, Weissleder R, Tung C-H. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol Cancer Ther. 2006;5:1944–9.
79. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat. 2007;10:207–17.
80. Ko J-K, Choi K-H, Pan Z, Lin P, Weisleder N, Kim C-W, et al. The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis. J Cell Sci. 2007;120:2912–23.
81. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183–92.
82. Mizukawa K, Kawamura A, Sasayama T, Tanaka K, Kamei M, Sasaki M, et al. Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J Neuro-Oncol. 2006;77:247–55.
83. Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012;119:810–6.
84. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10:806–16.
85. Shoshan-Barmatz V, Abu-Hamad S, Arzoine L, Zaid H. VDAC1 compositions and methods of use thereof for regulating apoptosis. ed: Google Patents, 2014.
86. Prezma T, Shteinfer A, Admoni L, Raviv Z, Sela I, Levi I, et al. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis. 2013;4:e809.
87. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One. 2008;3:e1852.
88. Smeele KM, Southworth R, Eeerbeek O, Wu R, Koeman A, Ardehali H, et al. Acute dissociation of hexokinase from mitochondria abrogates normal functioning, ischemic tolerance and ischemic preconditioning of the intact beating heart. Circulation. 2010;122:A15296.
89. Smolarczyk R, Cichoń T, Graja K, Hucz J, Sochanik A, Szala S. Antitumor effect of RGD-4C-GG-D (KLAKLAK) 2 peptide in mouse B16 (F10) melanoma model. Acta Biochim Pol. 2005;53:801–5.
90. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271:47–55.